Spruce Biosciences, Inc. Deferred Revenue
Spruce Biosciences, Inc. (SPRB) had Deferred Revenue of $0 as of 2024-12-31, per its 10-K filed 2025-04-15.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Current
us-gaap:DeferredRevenueCurrent · last filed 2025-04-15
- 2024-12-31: Deferred Revenue, Current $0.00.
- 2024-09-30: Deferred Revenue, Current $697.00K.
- 2024-06-30: Deferred Revenue, Current $1.30M.
- 2024-03-31: Deferred Revenue, Current $2.91M.
| Period end | Deferred Revenue, Current |
|---|---|
| 2024-12-31 | $0.00 10-K · filed 2025-04-15 |
| 2024-09-30 | $697.00K 10-Q · filed 2024-11-12 |
| 2024-06-30 | $1.30M 10-Q · filed 2024-08-12 |
| 2024-03-31 | $2.91M 10-Q · filed 2024-05-13 |
| 2023-12-31 | $4.91M 10-K · filed 2025-04-15 |
| 2023-09-30 | $7.80M 10-Q · filed 2023-11-13 |
| 2023-06-30 | $8.06M 10-Q · filed 2023-08-14 |
| 2023-03-31 | $9.21M 10-Q · filed 2023-05-15 |
| 2022-12-31 | $0.00 10-K · filed 2024-03-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Korro Bio, Inc. (KRRO) | United States | $0.141B | -1.81 |
| Atrium Therapeutics, Inc. (RNA) | United States | $0.140B | |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP) | United States | $0.144B | -1.72 |
| Curanex Pharmaceuticals Inc (CURX) | United States | $0.138B | |
| Annexon, Inc. (ANNX) | United States | $0.147B | -4.22 |
| TuHURA Biosciences, Inc./NV (HURA) | United States | $0.134B | -4.88 |
| Unicycive Therapeutics, Inc. (UNCY) | United States | $0.134B | -3.70 |
| NRX Pharmaceuticals, Inc. (NRXP) | United States | $0.131B | -6.31 |
| MEDICINOVA INC (MNOV) | United States | $0.130B | -6.04 |
| IMMUNIC, INC. (IMUX) | United States | $0.127B | -1.88 |